UTRN and cardiomyopathy: Our results demonstrate that WBPA treatment provides cardioprotection and improves myocyte function in dystrophin-deficient mdx mice with established cardiomyopathy by reducing intracellular Ca2+ and Na+ overload, reducing intracellular ROS generation, enhancing the expression of utrophin, reducing cardiomyocyte damage, with the end result of improvement of cell viability and contractile function.